The US IC device market will continue to be negatively affected by policies that contribute to declining ASPs, such as Medicare coverage for low-complexity catheterization procedures performed in nonhospital facilities, reimbursement equalization between different sites of service, and cost-containment measures. Moreover, the COVID-19 global pandemic will result in lost procedure volumes in the short term. However, these effects will be mitigated by the emergence of specialized premium-priced technologies to diagnose and treat complex CADs from 2022 through 2029.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for IC devices in the US, with market projections across a 10-year period.

A number of flagship DES devices were launched in recent years in the highly competitive DES market.

How have market dynamics changed between the three major competitors recently?

How has BIOTRONIK's Orsiro performed in the US market since its launch?

What competitive strategies are major competitors taking to gain market share in this market?

What is the developmental pipeline for the next generation of BRS?

The CMS continues to announce additional changes to Medicare coverage and reimbursement that will affect the IC device market in the coming years.

How have the first years of MACRA implementation affected the IC device market?

How will proposed rules in 2020 influence changes in site of service for PCI procedures?

What changes in reimbursement are expected to influence IC practices?

Emerging technologies designed to diagnose and treat complex PCIs are expected to receive approval in the US in the near future.

How will the adoption of alternative coronary physiology modalities such as resting indices, angiography-based FFR, and noninvasive FFRCT alter patient and procedure compositions in cardiac catheterization labs?

What is the status and expected impact of emerging balloon-based technologies such as DCBs and coronary lithotripsy?

The US IC device market will be impacted by the COVID-19 pandemic in the short term.

What factors will contribute to the market decline?

To what degree will the pandemic affect different procedures and devices?

How soon will procedure volumes, sales, and revenues recover over the forecast period?

Table of contents

  • Interventional Cardiology Devices - Market Insights - United States

Author(s): Xi Chen, PhD

Xi Chen is a manager on the Medtech Insights team at Decision Resources Group and currently serves as the in-house expert in general surgery, gastroenterology, ENT, and robotic surgery markets. Xi has been instrumental in improving the team’s market modeling capabilities and has also helped broaden the team’s expertise in leveraging medical claims and hospital purchase order data to perform market sizing and competitive analysis. Xi has been featured in several industry publications, particularly for his expertise in the robotic surgery market. Xi holds a Ph.D. in Biomedical Engineering from the University of Toronto.